Dongyuan Zhu

Jinan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial.

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial.

Journal: Frontiers in immunology

Published: March 06, 2026

Human Gallbladder Cancer Organoids.

Human Gallbladder Cancer Organoids.

Journal: Cell proliferation

Published: March 02, 2026

Human Pancreatic Cancer Organoids.

Human Pancreatic Cancer Organoids.

Journal: Cell proliferation

Published: March 02, 2026

HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial.

HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial.

Journal: Therapeutic advances in medical oncology

Published: January 28, 2026

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.

Journal: JAMA oncology

Published: January 02, 2026

Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.

Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.

Journal: Experimental hematology & oncology

Published: December 23, 2025

Integrative cfDNA profiling from low-pass whole-genome sequencing enables tissue-of-origin prediction in cancer.

Integrative cfDNA profiling from low-pass whole-genome sequencing enables tissue-of-origin prediction in cancer.

Journal: Molecular biomedicine

Published: October 24, 2025

Carelizumab and rivoceranib for advanced extramammary Paget's disease: an investigator-initiated multicenter, single-arm, phase II trial.

Carelizumab and rivoceranib for advanced extramammary Paget's disease: an investigator-initiated multicenter, single-arm, phase II trial.

Journal: The oncologist

Published: May 10, 2025

Sintilimab plus Anlotinib in Patients with Pretreated Locally Advanced or Metastatic Sarcoma: A Prospective, Single-Arm, Phase II Clinical Trial.

Sintilimab plus Anlotinib in Patients with Pretreated Locally Advanced or Metastatic Sarcoma: A Prospective, Single-Arm, Phase II Clinical Trial.

Journal: Cancer immunology research

Published: April 16, 2025

Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.

Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.

Journal: Cell reports. Medicine

Published: December 18, 2024

Two cases of inflammatory myofibroblastic tumor treated with targeted drugs: A case report.

Two cases of inflammatory myofibroblastic tumor treated with targeted drugs: A case report.

Journal: Medicine

Published: May 24, 2024

Administering immunotherapy after anti-vascular targeted therapy improves overall survival of patients with metastatic clear cell renal cell carcinoma.

Administering immunotherapy after anti-vascular targeted therapy improves overall survival of patients with metastatic clear cell renal cell carcinoma.

Journal: Journal of Cancer

Published: March 22, 2024

Showing 1-12 of 25

Last Updated: 09/26/2026